FDMT 4D Molecular Therapeutics, Inc.
Healthcare$8.71+1.28%ClosedMarket Cap: $455.3M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
1.30
P/S
5.09
EV/EBITDA
-2.22
DCF Value
$-10.93
FCF Yield
-28.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
-12.4%
Operating Margin
-203.5%
Net Margin
-182.3%
ROE
-36.8%
ROA
-31.4%
ROIC
-37.8%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $3.0M | 32.6% | $-73.6M | $-68.8M | $— | — |
| Q4 null | $85.1M | 97.7% | $14.7M | $19.4M | $— | — |
| FY null | $85.2M | 91.1% | $-159.5M | $-140.1M | $— | — |
| Q3 null | $90.0K | -52386.7% | $-61.2M | $-56.9M | $— | — |
| Q2 null | $15.0K | -319573.3% | $-59.5M | $-54.7M | $— | — |
| Q1 null | $14.0K | 100.0% | $-53.6M | $-48.0M | $— | — |
| Q4 null | $1.0K | -178300.0% | $-56.1M | $-49.7M | $— | — |
| FY null | $37.0K | 100.0% | $-187.8M | $-160.9M | $— | — |
| Q3 null | $3.0K | 100.0% | $-51.1M | $-43.8M | $— | — |
| Q2 null | $5.0K | -637100.0% | $-42.5M | $-35.0M | $— | — |
| Q1 null | $28.0K | -99435.7% | $-38.1M | $-32.4M | $— | — |
| Q4 2023 | $-19.0K | 137089.5% | $-36.7M | $-32.3M | $-0.83 | — |